Synergy Healthcare

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)6 trials
• Liver cirrhosis2 trials
• Chronic kidney disease1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Obesity1 trial
• Type 2 diabetes1 trial

Phase

• Phase 24 trials
• Phase 34 trials
• Phase 11 trial

Status

• Recruiting4 trials
• Active, not recruiting2 trials
• Completed2 trials
• Terminated1 trial

Lead sponsor

• Boehringer Ingelheim2 trials
• Eccogene1 trial
• Gilead Sciences1 trial
• Inventiva Pharma1 trial
• Novartis Pharmaceuticals1 trial
• and 3 more

Running trials

• Recruiting

  A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

  NCT07465653· Phase 1· Novartis Pharmaceuticals· Source

  Contact: Shannon Stickels

• Recruiting

  A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

  NCT07288138· Phase 2· Eccogene· Source

  Contact: Eccogene Clinical Trials

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

  NCT05979779· Phase 2· Rivus Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)3 recruiting
• Heart failure1 recruiting
• Liver cirrhosis1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

  NCT06897202· Phase 2· Pfizer· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source